The definitive reference for cannabis GMP, validation and regulatory affairs terminology. Authored by pharmaceutical manufacturing practitioners. Updated as the industry evolves.
The data integrity standard for GMP records. Attributable (records identify who made them and when), Legible (readable and permanent), Contemporaneous (recorded at the time of the activity), Original (first capture of data), Accurate (correct and truthful), plus Complete, Consistent, Enduring and Available. The ALCOA+ principles are the foundation of all GMP data integrity requirements under EU GMP and FDA guidance.
EU GMP Annex 1: Manufacture of Sterile Medicinal Products. The 2022 revision is the most significant update to European sterile manufacturing guidance in twenty years. Clause 4.4 requires all medicinal product manufacturers β including non-sterile cannabis facilities β to maintain a documented Contamination Control Strategy (CCS).
EU GMP Annex 11: Computerised Systems. Sets out the GMP requirements for computerised systems used in pharmaceutical manufacturing, including validation, access controls, audit trails and electronic records. Directly relevant to any cannabis facility using a LIMS, MES, ERP or electronic batch record system.
EU GMP Annex 15: Qualification and Validation. Defines the lifecycle approach to qualification and validation, covering design qualification, IQ, OQ, PQ, process validation, cleaning validation and ongoing monitoring. The primary EU GMP reference document for cannabis facility qualification programmes.
Active Pharmaceutical Ingredient. The biologically active component of a medicinal product. In cannabis, the APIs are typically delta-9-THC, CBD, or other cannabinoids. Cannabis APIs are subject to full EU GMP manufacturing requirements under Part II of the EU GMP guidelines.
A secure, computer-generated record that captures the date and time of operator entries and actions that create, modify or delete electronic records. Required under Annex 11 for all GMP computerised systems. Audit trails must be retained, regularly reviewed and protected from modification.
A health-based exposure limit representing the dose of a substance that is unlikely to cause adverse effects if a person is exposed at or below this level throughout their lifetime. Used in cleaning validation as the basis for Permitted Daily Exposure (PDE) calculations.
EU GMP Annex 1 β Manufacture of Sterile Medicinal Products. Revised 2022. Sets requirements for sterile manufacturing including the Contamination Control Strategy requirement now applicable to all medicinal product manufacturers.
A secure, computer-generated, time-stamped electronic record that allows reconstruction of the course of events relating to the creation, modification or deletion of an electronic record. Required under EU GMP Annex 11 for all computerised systems used in GMP.
The complete documentation for a single batch of medicinal product. Includes all manufacturing steps, in-process controls, deviations, analytical results and QA review. The batch record is the primary evidence base for the Qualified Person certification decision and must demonstrate that the batch was manufactured and tested in compliance with GMP.
Bundesinstitut fΓΌr Arzneimittel und Medizinprodukte. The Federal Institute for Drugs and Medical Devices β Germany's national competent authority for pharmaceutical regulation including medical cannabis. BfArM conducts independent assessments of cannabis supplier quality systems that go beyond reviewing EU GMP certificates, making it the most rigorous regulatory authority in the European cannabis market.
A defined quantity of starting material, packaging material or product processed in a single process or series of processes such that it could be expected to be homogeneous. Also called a lot.
The manufacturing record for a specific batch, providing a complete history of production. Must be complete (ALCOA+), reviewed by QA before release and retained per defined retention periods.
The total number of viable microorganisms on or in a product prior to sterilisation. Relevant for cannabis products as a specification parameter and for monitoring manufacturing environment hygiene.
A study conducted to establish equivalence between two analytical methods, manufacturing sites or product formulations, allowing data generated under one set of conditions to be used to support another.
Corrective and Preventive Action. A structured quality system mechanism for investigating deviations, complaints and audit findings, identifying root causes, implementing corrections and preventing recurrence. CAPA effectiveness must be verified after implementation. A mature CAPA system is a core GMP requirement and a primary indicator of quality culture maturity.
A non-intoxicating phytocannabinoid synthesised by the cannabis plant as CBDA and converted to CBD through decarboxylation. The primary active constituent of CBD-dominant medical cannabis products. CBD is subject to full pharmaceutical manufacturing standards when processed as a medicinal product.
A phytocannabinoid formed by the oxidative degradation of delta-9-THC. CBN content is a stability-indicating marker β elevated CBN signals THC degradation from exposure to oxygen, heat or light. CBN should appear in the specification of any THC-containing cannabis product as an upper-limit parameter.
Contamination Control Strategy. A planned set of controls derived from current product and process understanding that assures process performance and product quality. Required under EU GMP Annex 1 (2022) Clause 4.4 for all medicinal product manufacturers. A cannabis facility CCS must address microbial, particulate, chemical and cross-contamination risks specific to cannabis manufacturing.
A formal quality system process for managing changes to facilities, equipment, processes, materials, documents and computer systems. Changes must be assessed for GMP impact, validated where required and approved before implementation. Inadequate change control is one of the most common critical findings in pharmaceutical GMP inspections.
Certified Cannabis GMP Practitioner. An ECI professional certification for quality, manufacturing and regulatory professionals. Covers EU GMP fundamentals, documentation and CAPA management. The core GMP compliance credential and prerequisite for all other ECI certifications.
Certified Cannabis Pharmaceutical Scientist. An ECI professional certification for pharmacists, scientists and regulatory affairs professionals. Covers cannabinoid pharmacology, EU regulatory affairs, QC and formulation science. Requires CCGP as prerequisite.
Certified Cannabis Validation Professional. An ECI professional certification for engineers, validation specialists and CQV professionals. Covers IQ/OQ/PQ, facility qualification, utility qualification, analytical instrument qualification and computer system validation. Requires CCGP as prerequisite.
Critical Process Parameter. A process parameter whose variability has an impact on a critical quality attribute and should therefore be monitored or controlled to ensure the process produces the desired quality. Defining CPPs for critical cannabis manufacturing steps such as decarboxylation, extraction and formulation is a fundamental process validation requirement.
Critical Quality Attribute. A physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range or distribution to ensure the desired product quality. Cannabinoid content, CBN content, microbial load and pesticide residues are typical CQAs for cannabis medicinal products.
Commissioning, Qualification and Validation. The integrated programme covering facility commissioning, equipment and utility qualification, process validation and computer system validation. CQV is the engineering and quality discipline that demonstrates a pharmaceutical facility can consistently produce product meeting its specification.
The US FDA current Good Manufacturing Practice regulations for finished pharmaceuticals. Relevant reference for cannabis companies targeting the US market or for context when analysing FDA enforcement actions.
The set of operations that establish, under specified conditions, the relationship between values of quantities indicated by a measuring instrument and the corresponding values realised by standards. Calibrated instruments are a GMP requirement.
A statistical measure of process capability β the degree to which a process produces output within specification limits. Cpk β₯1.33 is generally considered capable; used in process validation and ongoing process verification.
A document issued by a manufacturer or testing laboratory confirming that a batch of material meets its specification. Cannabis starting material must be accompanied by a CoA reviewed before GMP release.
A document certifying that a product or material has been manufactured and/or tested in accordance with applicable GMP requirements and meets its specification.
A separation technique used in cannabis analytical testing. HPLC (high-performance liquid chromatography) is the primary method for cannabinoid potency testing; GC (gas chromatography) is used for terpene profiling and residual solvent analysis.
A room in which the concentration of airborne particles is controlled, and which is constructed and used in a manner to minimise the introduction, generation and retention of particles inside the room. Cannabis manufacturing typically uses Grade C and Grade D cleanrooms.
The process of verifying that equipment and systems have been installed correctly and are functioning as designed. Distinct from qualification β commissioning is an engineering activity; qualification is a GMP activity.
A pre-defined plan that describes the testing and criteria to be used when evaluating whether a manufacturing change has affected product quality. Allows post-approval changes without full regulatory re-submission where comparability is demonstrated.
Process validation conducted during routine production. Acceptable only in exceptional circumstances with regulatory pre-approval and strong process understanding from development.
Measures taken to prevent the spread of contamination β particularly cross-contamination β from one product, material or area to another. Critical in multi-product cannabis facilities.
Also called Stage 3 Validation. Ongoing assurance that the process remains in a state of control during routine production. Involves statistical process control, trending and annual product review.
A statistical process control tool used to monitor process parameters over time. Identifies trends, shifts and out-of-control conditions that require investigation. Used in Continued Process Verification programmes.
An action taken to eliminate the cause of a detected nonconformity or other undesirable situation. Distinguished from preventive action (which addresses potential non-conformities) in the CAPA system.
A step in a manufacturing process where a control measure can be applied and is essential to prevent or eliminate a safety hazard or reduce it to an acceptable level. Term from HACCP; applied in cannabis GMP contamination control.
A physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range or distribution to ensure the desired product quality. Cannabinoid potency, purity and microbial limits are CQAs for cannabis products.
Contamination of a starting material, intermediate or finished product with another starting material, intermediate or product. In cannabis manufacturing, THC-to-CBD cross-contamination is a critical patient safety risk requiring validated cleaning controls.
The degree to which data is complete, consistent and accurate throughout the data lifecycle. GMP data integrity requires that all records are ALCOA+ compliant, that electronic systems are validated with configured audit trails, and that data cannot be deleted, modified or obscured without detection. Data integrity failures are the most common critical finding in contemporary pharmaceutical GMP inspections.
The thermal conversion of acidic cannabinoids (THCA, CBDA) to their neutral pharmacologically active forms (THC, CBD) by the application of heat. A critical process step in cannabis manufacturing that must be formally validated, with critical process parameters defined and controlled, to ensure consistent product potency.
Any departure from an approved procedure, specification or standard. Deviations must be documented, investigated with root cause analysis, assessed for batch impact and closed with appropriate CAPA. A formal deviation management system is a core EU GMP requirement. Unmanaged deviations are a primary indicator of quality system immaturity.
The multidimensional combination and interaction of input variables and process parameters demonstrated to provide assurance of quality. Operating within the design space is not considered a change. Defined through process development studies and confirmed during process validation.
The completeness, consistency and accuracy of data. GMP data must be attributable, legible, contemporaneous, original, accurate (ALCOA) and additionally complete, consistent, enduring and available (ALCOA+).
Documented verification that the proposed design of a facility, system or equipment is suitable for its intended purpose. First stage in the qualification lifecycle.
The multidimensional combination and interaction of input variables and process parameters that have been demonstrated to provide assurance of quality. Operating within the design space is not considered a change; movement outside is.
The practice of alternating between two or more disinfectant classes to prevent the development of resistant microorganisms in the manufacturing environment. EU GMP Annex 1 requires use of a sporicide at defined frequency.
The system for managing documents throughout their lifecycle β creation, review, approval, distribution, use, revision and withdrawal. Core element of the pharmaceutical quality system.
European Medicines Agency. The EU regulatory body responsible for the scientific evaluation, supervision and safety monitoring of medicines. EMA guidance documents β including ICH quality guidelines adopted into EU GMP β are the primary authoritative references for pharmaceutical cannabis manufacturing standards.
The systematic sampling and testing of air, surfaces and personnel to detect microbial and particulate contamination in classified manufacturing areas. An Environmental Monitoring Programme (EMP) must be qualified, with sampling locations, frequencies and alert/action limits defined and justified. Results must be trended and excursions investigated.
European Union Good Manufacturing Practice. The regulatory standard governing the manufacture of medicinal products in Europe, published in EudraLex Volume 4. EU GMP applies to all licensed cannabis manufacturers and importers supplying European markets and is enforced through regulatory inspection by national competent authorities.
The collection of rules and regulations governing medicinal products in the EU, published by the European Commission. Volume 4 contains the EU GMP guidelines and is the primary regulatory reference document for all pharmaceutical cannabis manufacturing compliance.
The European database of EU GMP certificates, non-compliance statements and manufacturing authorisations. Publicly searchable. The primary public record of EU GMP-certified cannabis manufacturers.
Any substance other than the active pharmaceutical ingredient (API) that is included in a medicinal product formulation. Cannabis oil formulations include excipients such as carrier oils (sesame, MCT, olive oil).
A chemical that can be extracted from a container, closure or manufacturing equipment into a solvent under exaggerated conditions. Distinguished from leachable (which migrates under normal conditions of use).
Failure Mode and Effects Analysis. A systematic risk assessment tool used to identify potential failure modes in a process or system, assess their likelihood and impact, and prioritise controls. FMEA is widely used in cannabis facility Contamination Control Strategy development and validation risk assessments.
The collective process of qualifying the manufacturing facility including HVAC, classified zones, utilities and building management systems. Prerequisite for the environmental monitoring programme qualification and production.
A comprehensive analytical profile of a complex sample used to confirm identity. Applied in cannabis analysis to confirm batch-to-batch consistency of full-spectrum preparations through multi-analyte profiling.
An analytical technique for counting and characterising particles. Used in microbiology for rapid microbial enumeration as an alternative to traditional growth-based methods. Emerging application in pharmaceutical cannabis environmental monitoring.
The process of developing and producing a pharmaceutical dosage form combining the active ingredient(s) with excipients. Cannabis formulation includes oil preparations, capsules, sublingual sprays and oral solutions.
Good Agricultural and Collection Practice. The quality standard governing the cultivation, harvesting and primary processing of cannabis intended for medicinal use. GACP addresses site selection, growing environment, water quality, pesticide management, harvest, drying, documentation and traceability. GACP is the prerequisite quality framework before cannabis starting material enters the GMP manufacturing zone.
Good Documentation Practice. The standards ensuring that pharmaceutical records are accurate, complete and compliant. GDP requires that records are legible, contemporaneous, attributable and that corrections are made correctly β a single line through the original entry, initialled and dated, with the correction written alongside.
Good Manufacturing Practice. The system of quality assurance that ensures medicinal products are consistently produced and controlled to quality standards appropriate for their intended use. GMP covers premises, equipment, personnel, documentation, quality control and distribution. EU GMP is the applicable standard for medicinal cannabis manufacturing in Europe.
A systematic evaluation of a manufacturing operation against EU GMP requirements to identify areas of non-compliance or sub-optimal practice. The starting point for GMP implementation or remediation programmes.
A scientifically derived limit for acceptable exposure to a pharmaceutical substance, based on toxicological and pharmacological data. In cannabis manufacturing, health-based limits (expressed as PDE) must be used to set cleaning validation acceptance criteria for shared equipment.
Heating, Ventilation and Air Conditioning. The building services system responsible for maintaining classified area conditions including temperature, humidity, air pressure differentials and air change rates. HVAC qualification is fundamental for any cannabis facility with classified manufacturing areas.
High Efficiency Particulate Air filter. Required for supply air in pharmaceutical classified areas. H13 (99.95% efficiency) used in Grade D areas; H14 (99.995%) used in Grade A/B/C. Annual integrity testing required.
High-Performance Liquid Chromatography. The primary analytical technique for cannabinoid potency testing. Methods must be validated per ICH Q2(R1) before use for quality decisions.
The maximum time a material or intermediate can be held between manufacturing steps while maintaining quality. Hold times must be validated and documented in manufacturing procedures.
Uniformity of a substance or mixture. Critical for cannabis preparations β cannabinoid content must be homogeneous throughout a batch. Blend uniformity validation demonstrates homogeneity.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Develops internationally agreed quality guidelines including ICH Q8 (Pharmaceutical Development), ICH Q9 (Quality Risk Management) and ICH Q10 (Pharmaceutical Quality System). All are formally adopted into EU GMP.
In-Process Control. Checks performed during manufacturing to monitor and adjust the process and ensure product conforms to its specification. IPCs provide real-time quality assurance during production and must be documented in the batch record with defined acceptance criteria.
Installation Qualification. The documented verification that equipment, utilities and systems are installed correctly according to approved specifications. IQ is the first stage of the qualification lifecycle and establishes the baseline from which OQ and PQ proceed.
Pharmaceutical Quality System guideline. The framework for the lifecycle approach to pharmaceutical quality management, covering development, technology transfer, manufacturing and product discontinuation.
International Council for Harmonisation guideline on Validation of Analytical Procedures. Sets out the validation characteristics required for pharmaceutical analytical methods: specificity, linearity, accuracy, precision, range, detection limit, quantitation limit, robustness.
Checks performed during the manufacturing process to monitor and if necessary adjust the process to ensure conformity of the intermediate or finished product. Cannabis IPCs include cannabinoid content, CBN, moisture, pH and microbial bioburden.
Documented evidence that equipment or systems have been installed correctly in accordance with approved specifications. First stage of operational qualification; preceded by DQ.
A material produced during the steps of the processing of a starting material or active pharmaceutical substance that undergoes further molecular change or processing before it becomes an API or finished product.
ICH Q10 principle: systematic approaches to gathering, analysing, storing and disseminating information related to products, manufacturing processes and components. Supports continued GMP compliance through product lifecycle.
Laboratory Information Management System. A software system used to manage laboratory samples, workflows, analytical results and quality control data. In GMP manufacturing, a LIMS must be validated in accordance with Annex 11 before it is used to generate or manage GMP data.
Computerised system for managing laboratory samples, testing workflows, data management and reporting. Requires validation under Annex 11 where used in GMP decision-making.
A chemical compound that migrates from a container, closure or manufacturing equipment into the product under normal conditions of use. Distinguished from extractable (which requires exaggerated conditions).
The ICH Q8/Q9/Q10 principle that quality management activities should span the entire product lifecycle from development through manufacturing to product discontinuation.
The licence granted by a national competent authority permitting a facility to manufacture, import or export medicinal products. A Manufacturing Authorisation is a prerequisite for any facility supplying medicinal cannabis to European markets and is only granted after a successful GMP inspection.
The regulatory approval required to place a medicinal product on the market. Most medical cannabis products in Europe are currently supplied under special authorisation pathways rather than full Marketing Authorisation.
The approved template for the batch record of a specific product. All production batches are manufactured and documented according to the MBR. Controlled document; changes require change control.
Also called process simulation. A sterility test where microbiological growth media is processed using the same procedure as for the actual product to demonstrate the process controls are effective. Primarily relevant to sterile cannabis products.
The counting of viable microorganisms in a sample. For pharmaceutical cannabis products, TAMC (Total Aerobic Microbial Count) and TYMC (Total Yeasts and Moulds Count) are required per Ph. Eur. 2.6.12 and 2.6.13.
Any deviation from specified requirements. May be a product nonconformance (out-of-specification result), process nonconformance (departure from approved procedure) or system nonconformance (failure of quality system element).
Out of Specification. An analytical result falling outside the established acceptance criteria in the approved specification. OOS results must be formally investigated before a batch can be released or rejected. Phase 1 investigates laboratory error; Phase 2 investigates manufacturing causes.
Operational Qualification. The documented verification that equipment and systems operate consistently within defined limits when operated according to approved procedures. OQ follows IQ and precedes PQ, testing equipment across its full operational range including worst-case conditions.
Documented evidence that a piece of equipment or system operates within defined parameters within the design range. Follows IQ; precedes PQ.
A result that is within specification limits but represents a statistically significant deviation from historical data trends. OOT results require investigation to identify whether they indicate process drift before an OOS condition develops.
Permitted Daily Exposure. A health-based exposure limit representing the maximum acceptable daily intake of a residual pharmaceutical substance unlikely to cause adverse effects. PDEs must be used to calculate cleaning validation acceptance limits for shared equipment in cannabis manufacturing.
The process by which a cannabis operator progressively adopts the quality systems, validated processes, documentation standards and compliance infrastructure of pharmaceutical manufacturing. The defining operational challenge for licensed cannabis companies seeking to supply regulated European markets. The ECI SOMF provides a structured methodology for managing this transformation.
Performance Qualification. The documented verification that equipment and systems perform consistently and reproducibly within defined specifications under routine manufacturing conditions. PQ is the final stage of the qualification lifecycle.
The documented evidence that a manufacturing process, operated within established parameters, can perform effectively and reproducibly to produce a medicinal product meeting its specifications. Covers extraction, decarboxylation, formulation and packaging operations in cannabis manufacturing.
Release of product on the basis of process parameters (demonstrating that the process has been carried out correctly) rather than end-product testing. Not standard for cannabis products currently.
Unwanted mobile undissolved particles in a product. EU GMP Annex 1 sets particle count limits for classified zones by size (β₯0.5ΞΌm and β₯5.0ΞΌm). Continuous particle monitoring required in Grade C and above during production.
Equipment worn by personnel to protect them and/or the product from contamination. In cannabis classified areas, PPE includes cleanroom gowning, gloves, masks and dedicated footwear.
The principle that GMP requirements should be applied in a manner proportionate to the stage of clinical development β less stringent during early development, increasing as the product approaches commercial manufacture.
An action taken to prevent the occurrence of a potential nonconformity. Distinguished from corrective action (which addresses actual nonconformities). Both are elements of the pharmaceutical CAPA system.
A system for designing, analysing and controlling manufacturing processes through timely measurements of critical quality and performance attributes, with the goal of ensuring final product quality.
Process validation conducted prior to routine production β the standard approach for new products and processes. Distinguished from concurrent validation (during production) and retrospective validation (based on historical data).
Quality Management System. The organisational structure, procedures, processes and resources needed to implement quality management. A pharmaceutical QMS covers quality policy, SOPs, change control, CAPA, deviation management, internal audits and management review.
Qualified Person. An individual authorised to certify that each batch of medicinal product has been manufactured and tested in accordance with GMP requirements. A QP must be named on the Manufacturing Authorisation. Having a competent QP is a prerequisite for any cannabis facility supplying European markets.
The values, beliefs and behaviours that ensure quality is embedded throughout an organisation. Characterised by leadership accountability, open deviation reporting, data integrity as a non-negotiable standard and continuous improvement. Assessed during regulatory inspections and a leading indicator of sustained GMP compliance.
A systematic process for the assessment, control, communication and review of risks to quality. Governed by ICH Q9. In cannabis manufacturing, QRM underpins the Contamination Control Strategy, validation programme prioritisation and inspection readiness planning.
An individual legally responsible under European medicinal product legislation for certifying that each batch of medicinal product has been manufactured and tested in accordance with applicable GMP requirements.
The application of quality risk management principles to focus compliance effort proportionately on areas of greatest risk to product quality and patient safety. EU GMP expects a risk-based approach to qualification, validation, environmental monitoring, auditing and change control.
The original data from which the conclusions of a study or test are drawn. Under ALCOA+, raw data must be retained, attributable, legible and protected from falsification.
Validation based on accumulated historical batch manufacturing and testing data. Only applicable to established products; not acceptable for new products.
A systematic process of gathering, organising and analysing information to understand and characterise risk. ICH Q9(R1) provides the pharmaceutical industry framework for quality risk management.
A document describing the GMP-related activities of a manufacturing site. Provides an overview of the quality management system, manufacturing operations, quality control, contract arrangements, complaints and recalls. The primary reference document for regulatory inspectors assessing a facility.
Strategic Operational Maturity Framework. An ECI-developed framework for assessing the pharmaceutical readiness of cannabis manufacturing facilities across seven dimensions: Quality Systems, Validation, Compliance, Operations, People, Data Integrity and Risk Management. The ECI Pharmaceuticalisation Indexβ’ expands the SOMF into eight assessment pillars.
Standard Operating Procedure. A written document describing the steps to perform a specific operation in a consistent, controlled manner. SOPs are the backbone of a pharmaceutical QMS. All GMP activities must be covered by approved, version-controlled SOPs accessible to the personnel performing the activity.
Systematic testing of a medicinal product under defined storage conditions over defined time periods to establish shelf life and storage requirements. For cannabis products, stability studies must include cannabinoid content, CBN content, microbial quality and physical appearance.
A predefined plan specifying how, when, where and how much to sample for a specific purpose. Sampling plans must be statistically justified and documented in the relevant SOP or specification.
A document describing in detail the requirements with which a product, material or service must conform. Cannabis product specifications include cannabinoid profile, potency, microbiological limits, pesticides, heavy metals, residual solvents and appearance.
Delta-9-tetrahydrocannabinol. The primary intoxicating phytocannabinoid in cannabis, synthesised as THCA and converted to THC through decarboxylation. The scheduled controlled substance in most European jurisdictions. THC content is the primary driver of narcotics licensing, import authorisation requirements and cleaning validation limit-setting in cannabis manufacturing.
The ability to trace and follow cannabis material through all stages of cultivation, processing, manufacturing and distribution. Full traceability from seed to patient is a regulatory requirement in most European jurisdictions and a fundamental GMP expectation.
The transfer of manufacturing knowledge and processes from one manufacturing site to another, from development to manufacturing, or from one process to another. Requires documented validation to confirm the receiving site can consistently reproduce the product.
A deviation from the defined storage or processing temperature range. Must be documented as a deviation with an impact assessment on affected materials or products.
A measure of the total carbon in organic compounds in a water sample. Used as a purity indicator for purified water systems in pharmaceutical manufacturing. Lower TOC indicates higher purity.
User Requirement Specification. A document defining the functional and compliance requirements that a system, equipment or facility must meet. The URS is the foundation of the qualification lifecycle. GMP requirements including data integrity and audit trail requirements must be captured in the URS for any computerised system.
The documented act of demonstrating that a procedure, process, equipment, material, activity or system leads to the expected results. Encompasses process validation, cleaning validation, method validation and computer system validation. A validated state must be maintained through ongoing monitoring, change control and periodic review.
A document establishing the scope, approach, responsibilities and schedule for the qualification and validation activities at a manufacturing site. The VMP is the strategic document governing the entire validation programme and is a prerequisite for EU GMP certification.
The conditions or set of conditions in qualification or validation that pose the greatest chance of process or product failure compared to ideal conditions. Worst-case testing must be performed and documented for cleaning validation sampling, environmental monitoring location selection and process validation stress testing.
No terms found for that search. Suggest a term β
This glossary is authored by ECI practitioners with direct experience in pharmaceutical manufacturing and cannabis regulatory affairs. Definitions reflect the practical application of requirements in EU GMP, ICH guidelines and current regulatory guidance. This glossary is not legal advice and does not replace primary regulatory documents. Always verify requirements directly with the relevant national competent authority or regulatory text. Suggest a term or correction β